NCT05616468 is a EARLY_PHASE1 clinical trial of BGT007 Cell Injection in Nasopharyngeal Carcinoma, sponsored by The Affiliated Hospital of Xuzhou Medical University.

Who is sponsoring NCT05616468?

NCT05616468 is sponsored by The Affiliated Hospital of Xuzhou Medical University.

What drugs are being tested in NCT05616468?

Interventions in NCT05616468: BGT007 Cell Injection, Fludarabine, cyclophosphamide.

What condition does NCT05616468 study?

NCT05616468 studies Nasopharyngeal Carcinoma.

Is NCT05616468 still recruiting?

NCT05616468 is currently status unknown. Last updated 15 December 2022.

Last reviewed 2022-12-15 · How we verify

NCT05616468

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Status unknown EARLY_PHASE1 Last updated 15 December 2022

What this trial tests

EARLY_PHASE1 trial testing BGT007 Cell Injection in Nasopharyngeal Carcinoma in 23 participants. Status unknown.

Timeline

30 December 2022

Primary endpoint
1 December 2024

31 December 2025

Quick facts

Lead sponsor	The Affiliated Hospital of Xuzhou Medical University
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	30 December 2022
Primary completion	1 December 2024
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

BGT007 Cell Injection — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →
cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Who can join

Adults 18 to 75, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Novel Therapeutic Development for Nasopharyngeal Carcinoma.
Kim J, Lee Y, Kim S, Park JC. · · 2025 · PMID 41002550 · DOI 10.3390/curroncol32090479

Verify or expand the search:

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other The Affiliated Hospital of Xuzhou Medical University trials

Trials by the same sponsor.

NCT06683131 — Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary · Phase 4 · not yet recruiting
NCT07295366 — Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Cont · Phase 4 · recruiting
NCT07285395 — AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study · Phase 1 · recruiting
NCT07301372 — Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemi · Phase 4 · recruiting
NCT07133776 — Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Di · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05616468 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Xuzhou Medical University
Last refreshed: 15 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05616468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing